[1]	YANNY B, WINTERS A, BOUTROS S, et al. Hepatic encephalopathy challenges, burden, and diagnostic and therapeutic approach[J]. Clin Liver Dis, 2019, 23(4): 607-623. DOI: 10.1016/j.cld.2019.07.001. 本文引用 [1]

[2]	ELSAID MI, RUSTGI VK. Epidemiology of hepatic encephalopathy[J]. Clin Liver Dis, 2020, 24(2): 157-174. DOI: 10.1016/j.cld.2020.01.001. 本文引用 [1]

[3]	TAPPER EB, ABERASTURI D, ZHAO Z, et al. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis[J]. Aliment Pharmacol Ther, 2020, 51(12): 1397-1405. DOI: 10.1111/apt.15749. 本文引用 [1]

[4]	MIRZAEI R, BOUZARI B, HOSSEINI-FARD SR, et al. Role of microbiota-derived short-chain fatty acids in nervous system disorders[J]. Biomed Pharmacother, 2021, 139: 111661. DOI: 10.1016/j.biopha.2021.111661. 本文引用 [1]

[5]	FERNANDES J, SU W, RAHAT-ROZENBLOOM S, et al. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans[J]. Nutr Diabetes, 2014, 4(6): e121. DOI: 10.1038/nutd.2014.23. 本文引用 [1]

[6]	YANG HJ, KIM JH. Role of microbiome and its metabolite, short chain fatty acid in prostate cancer[J]. Investig Clin Urol, 2023, 64(1): 3-12. DOI: 10.4111/icu.20220370. 本文引用 [1]

[7]	de VADDER F, KOVATCHEVA-DATCHARY P, GONCALVES D, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits[J]. Cell, 2014, 156(1-2): 84-96. DOI: 10.1016/j.cell.2013.12.016. 本文引用 [1]

[8]	BERGMAN EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species[J]. Physiol Rev, 1990, 70(2): 567-590. DOI: 10.1152/physrev.1990.70.2.567. 本文引用 [1]

[9]	COMALADA M, BAILÓN E, DE HARO O, et al. The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype[J]. J Cancer Res Clin Oncol, 2006, 132(8): 487-497. DOI: 10.1007/s00432-006-0092-x. 本文引用 [1]

[10]	MACHADO MG, PATENTE TA, ROUILLÉ Y, et al. Acetate improves the killing of Streptococcus pneumoniae by alveolar macrophages via NLRP3 inflammasome and glycolysis-HIF-1α axis[J]. Front Immunol, 2022, 13: 773261. DOI: 10.3389/fimmu.2022.773261. 本文引用 [1]

[11]	LANGE O, PROCZKO-STEPANIAK M, MIKA A. Short-chain fatty acids-a product of the microbiome and its participation in two-way communication on the microbiome-host mammal line[J]. Curr Obes Rep, 2023, 12(2): 108-126. DOI: 10.1007/s13679-023-00503-6. 本文引用 [1]

[12]	YANG M, ZHANG CY. G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment[J]. World J Gastroenterol, 2021, 27(8): 677-691. DOI: 10.3748/wjg.v27.i8.677. 本文引用 [1]

[13]	ZHANG L, SHI XH, QIU HM, et al. Protein modification by short-chain fatty acid metabolites in sepsis: A comprehensive review[J]. Front Immunol, 2023, 14: 1171834. DOI: 10.3389/fimmu.2023.1171834. 本文引用 [1]

[14]	KAISAR MMM, PELGROM LR, VAN DER HAM AJ, et al. Butyrate conditions human dendritic cells to prime type 1 regulatory T cells via both histone deacetylase inhibition and G protein-coupled receptor 109A signaling[J]. Front Immunol, 2017, 8: 1429. DOI: 10.3389/fimmu.2017.01429. 本文引用 [1]

[15]	LIU L, LI L, MIN J, et al. Butyrate interferes with the differentiation and function of human monocyte-derived dendritic cells[J]. Cell Immunol, 2012, 277(1-2): 66-73. DOI: 10.1016/j.cellimm.2012.05.011. 本文引用 [1]

[16]	NASTASI C, FREDHOLM S, WILLERSLEV-OLSEN A, et al. Butyrate and propionate inhibit antigen-specific CD8+ T cell activation by suppressing IL-12 production by antigen-presenting cells[J]. Sci Rep, 2017, 7(1): 14516. DOI: 10.1038/s41598-017-15099-w. 本文引用 [1]

[17]	TAN J, MCKENZIE C, VUILLERMIN PJ, et al. Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways[J]. Cell Rep, 2016, 15(12): 2809-2824. DOI: 10.1016/j.celrep.2016.05.047. 本文引用 [1]

[18]	SCHULTHESS J, PANDEY S, CAPITANI M, et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages[J]. Immunity, 2019, 50(2): 432-445. DOI: 10.1016/j.immuni.2018.12.018. 本文引用 [1]

[19]	CHANG PV, HAO LM, OFFERMANNS S, et al. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition[J]. Proc Natl Acad Sci U S A, 2014, 111(6): 2247-2252. DOI: 10.1073/pnas.1322269111. 本文引用 [2]

[20]	HUANG CR, DU W, NI YM, et al. The effect of short-chain fatty acids on M2 macrophages polarization in vitro and in vivo[J]. Clin Exp Immunol, 2022, 207(1): 53-64. DOI: 10.1093/cei/uxab028. 本文引用 [1]

[21]	LI GF, LIN J, ZHANG C, et al. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease[J]. Gut Microbes, 2021, 13(1): 1968257. DOI: 10.1080/19490976.2021.1968257. 本文引用 [1]

[22]	AOYAMA M, KOTANI J, USAMI M. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways[J]. Nutrition, 2010, 26(6): 653-661. DOI: 10.1016/j.nut.2009.07.006. 本文引用 [1]

[23]	VINOLO MA, RODRIGUES HG, HATANAKA E, et al. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils[J]. J Nutr Biochem, 2011, 22(9): 849-855. DOI: 10.1016/j.jnutbio.2010.07.009. 本文引用 [1]

[24]	TEDELIND S, WESTBERG F, KJERRULF M, et al. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: A study with relevance to inflammatory bowel disease[J]. World J Gastroenterol, 2007, 13(20): 2826-2832. DOI: 10.3748/wjg.v13.i20.2826. 本文引用 [1]

[25]	THEILER A, BÄRNTHALER T, PLATZER W, et al. Butyrate ameliorates allergic airway inflammation by limiting eosinophil trafficking and survival[J]. J Allergy Clin Immunol, 2019, 144(3): 764-776. DOI: 10.1016/j.jaci.2019.05.002. 本文引用 [1]

[26]	SHI YB, XU MZ, PAN S, et al. Induction of the apoptosis, degranulation and IL-13 production of human basophils by butyrate and propionate via suppression of histone deacetylation[J]. Immunology, 2021, 164(2): 292-304. DOI: 10.1111/imm.13370. 本文引用 [1]

[27]	FACHI JL, SÉCCA C, RODRIGUES PB, et al. Acetate coordinates neutrophil and ILC3 responses against C. difficile through FFAR2[J]. J Exp Med, 2020, 217(3): e20190489. DOI: 10.1084/jem.20190489. 本文引用 [1]

[28]	SERAFINI N, JARADE A, SURACE L, et al. Trained ILC3 responses promote intestinal defense[J]. Science, 2022, 375(6583): 859-863. DOI: 10.1126/science.aaz8777. 本文引用 [1]

[29]	YANG WJ, YU TM, HUANG XS, et al. Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity[J]. Nat Commun, 2020, 11(1): 4457. DOI: 10.1038/s41467-020-18262-6. 本文引用 [1]

[30]	THIO CL, CHI PY, LAI AC, et al. Regulation of type 2 innate lymphoid cell-dependent airway hyperreactivity by butyrate[J]. J Allergy Clin Immunol, 2018, 142(6): 1867-1883. DOI: 10.1016/j.jaci.2018.02.032. 本文引用 [1]

[31]	CHUN E, LAVOIE S, FONSECA-PEREIRA D, et al. Metabolite-sensing receptor Ffar2 regulates colonic group 3 innate lymphoid cells and gut immunity[J]. Immunity, 2019, 51(5): 871-884. DOI: 10.1016/j.immuni.2019.09.014. 本文引用 [1]

[32]	KIBBIE JJ, DILLON SM, THOMPSON TA, et al. Butyrate directly decreases human gut lamina propria CD4 T cell function through histone deacetylase (HDAC) inhibition and GPR43 signaling[J]. Immunobiology, 2021, 226(5): 152126. DOI: 10.1016/j.imbio.2021.152126. 本文引用 [1]

[33]	FURUSAWA Y, OBATA Y, FUKUDA S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells[J]. Nature, 2013, 504(7480): 446-450. DOI: 10.1038/nature12721. 本文引用 [1]

[34]	SINGH N, GURAV A, SIVAPRAKASAM S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis[J]. Immunity, 2014, 40(1): 128-139. DOI: 10.1016/j.immuni.2013.12.007. 本文引用 [1]

[35]	BACHEM A, MAKHLOUF C, BINGER KJ, et al. Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8+ T cells[J]. Immunity, 2019, 51(2): 285-297. DOI: 10.1016/j.immuni.2019.06.002. 本文引用 [1]

[36]	MEYER F, SEIBERT FS, NIENEN M, et al. Propionate supplementation promotes the expansion of peripheral regulatory T-Cells in patients with end-stage renal disease[J]. J Nephrol, 2020, 33(4): 817-827. DOI: 10.1007/s40620-019-00694-z. 本文引用 [1]

[37]	ARPAIA N, CAMPBELL C, FAN XY, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation[J]. Nature, 2013, 504(7480): 451-455. DOI: 10.1038/nature12726. 本文引用 [1]

[38]	WU W, SUN M, CHEN F, et al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43[J]. Mucosal Immunol, 2017, 10(4): 946-956. DOI: 10.1038/mi.2016.114. 本文引用 [1]

[39]	DAÏEN CI, TAN J, AUDO R, et al. Gut-derived acetate promotes B10 cells with antiinflammatory effects[J]. JCI Insight, 2021, 6(7): e144156. DOI: 10.1172/jci.insight.144156. 本文引用 [1]

[40]	TIAN GX, PENG KP, YU Y, et al. Propionic acid regulates immune tolerant properties in B Cells[J]. J Cell Mol Med, 2022, 26(10): 2766-2776. DOI: 10.1111/jcmm.17287. 本文引用 [1]

[41]	ROSSER EC, PIPER CJM, MATEI DE, et al. Microbiota-derived metabolites suppress arthritis by amplifying aryl-hydrocarbon receptor activation in regulatory B cells[J]. Cell Metab, 2020, 31(4): 837-851. DOI: 10.1016/j.cmet.2020.03.003. 本文引用 [1]

[42]	KIM DS, WOO JS, MIN HK, et al. Short-chain fatty acid butyrate induces IL-10-producing B cells by regulating circadian-clock-related genes to ameliorate Sjögren’s syndrome[J]. J Autoimmun, 2021, 119: 102611. DOI: 10.1016/j.jaut.2021.102611. 本文引用 [1]

[43]	SANCHEZ HN, MORONEY JB, GAN HQ, et al. B cell-intrinsic epigenetic modulation of antibody responses by dietary fiber-derived short-chain fatty acids[J]. Nat Commun, 2020, 11(1): 60. DOI: 10.1038/s41467-019-13603-6. 本文引用 [1]

[44]	BLOEMEN JG, VENEMA K, van de POLL MC, et al. Short chain fatty acids exchange across the gut and liver in humans measured at surgery[J]. Clin Nutr, 2009, 28(6): 657-661. DOI: 10.1016/j.clnu.2009.05.011. 本文引用 [1]

[45]	LIWINSKI T, CASAR C, RUEHLEMANN MC, et al. A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2020, 51(12): 1417-1428. DOI: 10.1111/apt.15754. 本文引用 [2]

[46]	KUMMEN M, THINGHOLM LB, RÜHLEMANN MC, et al. Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis[J]. Gastroenterology, 2021, 160(5): 1784-1798. DOI: 10.1053/j.gastro.2020.12.058.

[47]	CORNEJO-PAREJA I, AMIAR MR, OCAÑA-WILHELMI L, et al. Non-alcoholic fatty liver disease in patients with morbid obesity: The gut microbiota axis as a potential pathophysiology mechanism[J]. J Gastroenterol, 2024, 59(4): 329-341. DOI: 10.1007/s00535-023-02075-7. 本文引用 [1]

[48]	BRÜSSOW H, PARKINSON SJ. You are what you eat[J]. Nat Biotechnol, 2014, 32(3): 243-245. DOI: 10.1038/nbt.2845. 本文引用 [1]

[49]	DEN BESTEN G, BLEEKER A, GERDING A, et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation[J]. Diabetes, 2015, 64(7): 2398-2408. DOI: 10.2337/db14-1213. 本文引用 [1]

[50]	DENG MJ, QU F, CHEN L, et al. SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD[J]. J Endocrinol, 2020, 245(3): 425-437. DOI: 10.1530/JOE-20-0018. 本文引用 [1]

[51]	WEI YR, LI YM, YAN L, et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut, 2020, 69(3): 569-577. DOI: 10.1136/gutjnl-2018-317836. 本文引用 [1]

[52]	AWONIYI M, WANG J, NGO B, et al. Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC[J]. Gut, 2023, 72(4): 671-685. DOI: 10.1136/gutjnl-2021-326500. 本文引用 [1]

[53]	SINGH V, YEOH BS, CHASSAING B, et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer[J]. Cell, 2018, 175(3): 679-694. DOI: 10.1016/j.cell.2018.09.004. 本文引用 [1]

[54]	BEHARY J, AMORIM N, JIANG XT, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma[J]. Nat Commun, 2021, 12(1): 187. DOI: 10.1038/s41467-020-20422-7. 本文引用 [1]

[55]	PRATT M, FORBES JD, KNOX NC, et al. Microbiome-mediated immune signaling in inflammatory bowel disease and colorectal cancer: Support from meta-omics data[J]. Front Cell Dev Biol, 2021, 9: 716604. DOI: 10.3389/fcell.2021.716604. 本文引用 [1]

[56]	HANUS M, PARADA-VENEGAS D, LANDSKRON G, et al. Immune system, microbiota, and microbial metabolites: The unresolved triad in colorectal cancer microenvironment[J]. Front Immunol, 2021, 12: 612826. DOI: 10.3389/fimmu.2021.612826. 本文引用 [1]

[57]	KIRUNDI J, MOGHADAMRAD S, URBANIAK C. Microbiome-liver crosstalk: A multihit therapeutic target for liver disease[J]. World J Gastroenterol, 2023, 29(11): 1651-1668. DOI: 10.3748/wjg.v29.i11.1651. 本文引用 [1]

[58]	CUMMINGS JH, POMARE EW, BRANCH WJ, et al. Short chain fatty acids in human large intestine, portal, hepatic and venous blood[J]. Gut, 1987, 28(10): 1221-1227. DOI: 10.1136/gut.28.10.1221. 本文引用 [1]

[59]	SIVAPRAKASAM S, BHUTIA YD, YANG SP, et al. Short-chain fatty acid transporters: Role in colonic homeostasis[J]. Compr Physiol, 2017, 8(1): 299-314. DOI: 10.1002/cphy.c170014. 本文引用 [1]

[60]	FRANK DN, AMAND AL ST, FELDMAN RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases[J]. Proc Natl Acad Sci U S A, 2007, 104(34): 13780-13785. DOI: 10.1073/pnas.0706625104. 本文引用 [1]

[61]	MIRZAEI R, AFAGHI A, BABAKHANI S, et al. Role of microbiota-derived short-chain fatty acids in cancer development and prevention[J]. Biomed Pharmacother, 2021, 139: 111619. DOI: 10.1016/j.biopha.2021.111619. 本文引用 [1]

[62]	MA JY, PIAO XS, MAHFUZ S, et al. The interaction among gut microbes, the intestinal barrier and short chain fatty acids[J]. Anim Nutr, 2021, 9: 159-174. DOI: 10.1016/j.aninu.2021.09.012. 本文引用 [1]

[63]	PARADA VENEGAS D, de la FUENTE MK, LANDSKRON G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases[J]. Front Immunol, 2019, 10: 277. DOI: 10.3389/fimmu.2019.00277. 本文引用 [1]

[64]	AGIRMAN G, YU KB, HSIAO EY. Signaling inflammation across the gut-brain axis[J]. Science, 2021, 374(6571): 1087-1092. DOI: 10.1126/science.abi6087. 本文引用 [1]

[65]	ASHIQUE S, MOHANTO S, AHMED MG, et al. Gut-brain axis: A cutting-edge approach to target neurological disorders and potential synbiotic application[J]. Heliyon, 2024, 10(13): e34092. DOI: 10.1016/j.heliyon.2024.e34092. 本文引用 [1]

[66]	LIU JM, LI HJ, GONG TY, et al. Anti-neuroinflammatory effect of short-chain fatty acid acetate against Alzheimer’s disease via upregulating GPR41 and inhibiting ERK/JNK/NF-κB[J]. J Agric Food Chem, 2020, 68(27): 7152-7161. DOI: 10.1021/acs.jafc.0c02807. 本文引用 [1]

[67]	CHEN RZ, XU Y, WU P, et al. Transplantation of fecal microbiota rich in short chain fatty acids and butyric acid treat cerebral ischemic stroke by regulating gut microbiota[J]. Pharmacol Res, 2019, 148: 104403. DOI: 10.1016/j.phrs.2019.104403. 本文引用 [1]

[68]	ERNY D, HRABĚ DE ANGELIS AL, JAITIN D, et al. Host microbiota constantly control maturation and function of microglia in the CNS[J]. Nat Neurosci, 2015, 18(7): 965-977. DOI: 10.1038/nn.4030. 本文引用 [1]

[69]	BRANISTE V, AL-ASMAKH M, KOWAL C, et al. The gut microbiota influences blood-brain barrier permeability in mice[J]. Sci Transl Med, 2014, 6(263): 263ra158. DOI: 10.1126/scitranslmed.3009759. 本文引用 [1]

[70]	WYSS MT, MAGISTRETTI PJ, BUCK A, et al. Labeled acetate as a marker of astrocytic metabolism[J]. J Cereb Blood Flow Metab, 2011, 31(8): 1668-1674. DOI: 10.1038/jcbfm.2011.84. 本文引用 [1]

[71]	KOH A, de VADDER F, KOVATCHEVA-DATCHARY P, et al. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites[J]. Cell, 2016, 165(6): 1332-1345. DOI: 10.1016/j.cell.2016.05.041. 本文引用 [1]

[72]	PABST O, HORNEF MW, SCHAAP FG, et al. Gut-liver axis: Barriers and functional circuits[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(7): 447-461. DOI: 10.1038/s41575-023-00771-6. 本文引用 [1]

[73]	BLOOM PP, TAPPER EB, YOUNG VB, et al. Microbiome therapeutics for hepatic encephalopathy[J]. J Hepatol, 2021, 75(6): 1452-1464. DOI: 10.1016/j.jhep.2021.08.004. 本文引用 [1]

[74]	BLOOM PP, LUÉVANO JM Jr, MILLER KJ, et al. Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy[J]. Ann Hepatol, 2021, 25: 100333. DOI: 10.1016/j.aohep.2021.100333. 本文引用 [1]

[75]	WANG Q, CHEN CX, ZUO S, et al. Integrative analysis of the gut microbiota and faecal and serum short-chain fatty acids and tryptophan metabolites in patients with cirrhosis and hepatic encephalopathy[J]. J Transl Med, 2023, 21(1): 395. DOI: 10.1186/s12967-023-04262-9. 本文引用 [2]

[76]	BAJAJ JS. The role of microbiota in hepatic encephalopathy[J]. Gut Microbes, 2014, 5(3): 397-403. DOI: 10.4161/gmic.28684. 本文引用 [1]

[77]	JUANOLA O, FERRUSQUÍA-ACOSTA J, GARCÍA-VILLALBA R, et al. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis[J]. FASEB J, 2019, 33(10): 11595-11605. DOI: 10.1096/fj.201901327R. 本文引用 [1]

[78]	ZHU RR, LIU LW, ZHANG GZ, et al. The pathogenesis of gut microbiota in hepatic encephalopathy by the gut-liver-brain axis[J]. Biosci Rep, 2023, 43(6): BSR20222524. DOI: 10.1042/BSR20222524. 本文引用 [1]